Advertisement
Australia markets closed
  • ALL ORDS

    8,034.90
    -23.70 (-0.29%)
     
  • AUD/USD

    0.6664
    +0.0006 (+0.09%)
     
  • ASX 200

    7,766.70
    -21.60 (-0.28%)
     
  • OIL

    78.76
    +1.04 (+1.34%)
     
  • GOLD

    2,344.10
    +9.60 (+0.41%)
     
  • Bitcoin AUD

    101,627.35
    -1,444.84 (-1.40%)
     
  • CMC Crypto 200

    1,473.59
    -22.87 (-1.53%)
     

Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference

Opthea Limited
Opthea Limited

MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.

23rd Annual Needham Virtual Healthcare Conference Presentation Details:

Date:

Thursday, April 11th

Time:

3:45 p.m. ET

Presenter:

Frederic Guerard, Pharm D, CEO

Webcast Link

Here

 

 

A webcast of the Needham presentation can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website, www.opthea.com.

ADVERTISEMENT

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea’s lead product candidate, sozinibercept, is being evaluated in two pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610,) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve overall efficacy and deliver superior vision gains compared to the standard-of-care anti-VEGF-A agents. To learn more, visit our website and follow us on X and LinkedIn.

Authorized for release to ASX by Fred Guerard, CEO

Investor Enquiries

PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579

Media:

Silvana Guerci-Lena
NorthStream Global Partners
silvana@nsgpllc.com

Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com, Web: www.opthea.com